The CBX3 Knockout A-549 Polyclonal Cells represent a versatile loss-of-function tool generated by CRISPR/Cas9-mediated disruption of the CBX3 gene in the A-549 human lung adenocarcinoma cell background. This polyclonal knockout population provides a heterogeneous pool of edited cells, each carrying distinct disruptive modifications at the target locus, resulting in a mixed population with reduced or ablated CBX3 protein expression. This format is particularly useful for studying gene function without the selective pressure of clonal isolation, preserving cellular diversity and enabling robust phenotypic screening in a near-native tumor cell context.
The host A-549 cell line, derived from the lung adenocarcinoma of a 58-year-old Caucasian male, is an established epithelial model for lung cancer research. These adherent cells retain key features of type II pneumocyte origin and harbor genetic alterations common in non-small cell lung cancer, including KRAS mutation and wild-type EGFR. Widely employed in drug discovery, signal transduction studies, and cancer biology, A-549 cells provide a clinically relevant system to interrogate tumor-specific epigenetic mechanisms.
CBX3 encodes HP1??, a core component of the heterochromatin protein 1 family that bridges histone modifications and chromatin architecture. HP1?? specifically recognizes trimethylated histone H3 at lysine 9 (H3K9me3) through its chromodomain, promoting chromatin compaction and long-term transcriptional silencing. Upstream H3K9 methyltransferases such as SUV39H1, SUV39H2, and SETDB1 deposit the H3K9me3 mark, which serves as a docking platform for CBX3. In turn, CBX3 recruits additional silencing factors including DNMT1, CHAF1A, and the Lamin B receptor, reinforcing heterochromatin assembly and maintenance. Downstream, this complex mediates spreading of H3K9me3 and stable repression of target genes, thereby controlling critical processes like cell cycle progression and differentiation.
In the lung adenocarcinoma setting, dysregulation of CBX3 and H3K9me3 dynamics has been implicated in oncogenic programs, making A-549 cells an ideal model to dissect these relationships. Loss of CBX3 function in this polyclonal knockout background permits systematic evaluation of HP1??-dependent gene silencing on proliferation, clonogenicity, and drug responses. Given the gene??s association with both lung and breast cancer, as well as developmental disorders, this model aids in exploring how heterochromatin perturbations contribute to tumorigenesis and aberrant differentiation.
Researchers can employ these polyclonal CBX3 knockout cells in a broad range of epigenetics and cancer biology applications, including chromatin immunoprecipitation coupled with qPCR (ChIP-qPCR) to profile H3K9me3 occupancy, western blotting and immunofluorescence to assess CBX3 expression levels, and RNA sequencing to uncover transcriptomic changes following gene disruption. Cell proliferation and viability assays further extend the utility to functional genomic screens and drug sensitivity profiling. The model is particularly suited for investigating gene silencing mechanisms in the context of lung adenocarcinoma and for validating epigenetic targets. For additional technical specifications or custom inquiry, please contact Ascent Research.
